Academia.eduAcademia.edu

Outline

Title
Abstract
Introduction
Conclusions
References
All Topics
Psychology
Cognitive Psychology

Aboulia: neurobehavioural dysfunction of dopaminergic system?

Profile image of Gavin S DaweGavin S Dawe

2000, Medical Hypotheses

https://doi.org/10.1054/MEHY.1999.0890
visibility

…

description

8 pages

link

1 file

Abstract

Recent advances in the understanding of the neural substrates of goal-directed behaviour have created new interest in unlocking the mystery behind those disorders that are characterized by poverty of thought and action. In this review, various studies will be considered which proffer converging evidence that the dopaminergic brain circuitry running from ventral tegmental areas in the midbrain, via nucleus accumbens in the forebrain, to the frontal cortex, tends to produce aboulia when its restitutive function fails. Such aboulic deficits occur in various neurological and psychiatric disorders in which they have profound implications for the patients' management, rehabilitation and social interactions. We begin by examining the consequences of dopamine agonism and antagonism in pre-clinical studies and draw on the inferences that can be made from studies in humans. We then go on to discuss aboulic features in neuropsychiatric conditions, focusing on clinical manifestation, animal models, abnormal dopamine activity and pharmacological interventions.

Related papers

Nucleus accumbens dopamine and discriminated approach learning: interactive effects of 6-hydroxydopamine lesions and systemic apomorphine administration
David Theobald

Psychopharmacology, 2002

Rationale: Although dopaminergic mechanisms have been implicated in incentive motivational processes, their role in appetitive conditioning remains poorly understood. Objectives: To investigate the effects of dopamine (DA) depleting lesions of the nucleus accumbens and the direct acting dopamine receptor agonist apomorphine on the learning of discriminated appetitive approach behavior in a Pavlovian autoshaping paradigm. Methods: Rats received bilateral infusions of either phosphate-buffered saline (shams) or 6-hydroxydopamine (lesions) directly into the nucleus accumbens. Ten days later, rats were trained on an autoshaping task whereby a previously neutral light stimulus was paired with food reward. Presentation of another stimulus (CS-) was never followed by reward. Over 100 pairings subjects developed a conditioned response of approaching the reward-predictive stimulus (CS+). Prior to each autoshaping session subjects were administered either saline (1 ml/kg SC) or apomorphine (30 µg/kg; 100 µg/kg), in a between-subjects design. Results: Lesioned subjects showed a delay in the acquisition of discriminated approach and were insensitive to a subsequent change in the contingency of the task whereby approaches to the CS+ now prevented food delivery. Low dose apomorphine profoundly impaired learning in both sham and lesioned subjects. Despite increasing the overall number of CS+ and CS-approaches, the higher dose of apomorphine allowed discriminated approach in sham-operated animals only. Conclusions: These data are compatible with the hypothesis that nucleus accumbens dopamine serves to energize rather than guide conditioned approach to appetitive cues. They also support the notion that DA inputs in this region confer flexibility of approach to cues predictive of reward.

View PDFchevron_right
Reliance on habits at the expense of goal-directed control following dopamine precursor depletion
Elise Devito

Psychopharmacology, 2012

Rationale Dopamine is well known to play an important role in learning and motivation. Recent animal studies have implicated dopamine in the reinforcement of stimulusresponse habits, as well as in flexible, goal-directed action. However, the role of dopamine in human action control is still not well understood. Objectives We present the first investigation of the effect of reducing dopamine function in healthy volunteers on the balance between habitual and goal-directed action control. Methods The dietary intervention of acute dietary phenylalanine and tyrosine depletion (APTD) was adopted to study the effects of reduced global dopamine function on action control. Participants were randomly assigned to either the APTD or placebo group (ns=14) to allow for a between-subjects comparison of performance on a novel three-stage experimental paradigm. In the initial learning phase, participants learned to respond to different stimuli in order to gain rewarding outcomes. Subsequently, an outcome-devaluation test and a slips-of-action test were conducted to assess whether participants were able to flexibly adjust their behaviour to changes in the desirability of the outcomes. Results APTD did not prevent stimulus-response learning, nor did we find evidence for impaired response-outcome learning in the subsequent outcome-devaluation test. However, when goal-directed and habitual systems competed for control in the slips-of-action test, APTD tipped the balance Electronic supplementary material The online version of this article (towards habitual control. These findings were restricted to female volunteers. Conclusions We provide direct evidence that the balance between goal-directed and habitual control in humans is dopamine dependent. The results are discussed in light of gender differences in dopamine function and psychopathologies.

View PDFchevron_right
Adverse effect of dopamine agonist therapy in a patient with motor-intentional neglect
A.M. Barrett

Archives of Physical Medicine and Rehabilitation, 1999

Studies in animals and humans report dopamine agonists can improve neglect. Because dopamine deficit reduces intention to act, it has been suspected the dopamine agonist bromocriptine would improve deficient hemispatial intention. Thus, the effect of bromocriptine on line bisection was examined in a patient with neglect and failure of the action-intention system. The 5%year-old patient had left-sided neglect from a right cerebral infarction involving both cortical and subcortical (striatal) structures. It was determined that neglect on a line bisection task was attributable to a motor-intentional bias by testing under congruous and incongruous video monitoring. Testing sessions were held before starting bromocriptine, on 20mg/d, and after stopping bromocriptine. The patient's ipsilesional bias increased on bromocriptine, and improved when bromocriptine was stopped. Bromocriptine may worsen neglect if putamenal receptors are damaged. Dopamine agonists may activate the normal hemisphere, increasing an intentional bias. Clinicians using dopaminergic pharmacotherapy should assess patients for this possible adverse effect. 0 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation U NILATERAL NEGLECT, defined as a failure to report, respond, or orient to a stimulus in the side of space opposite a brain lesion, often follows right-sided brain damage, and can be induced by dysfunction in cortical and subcortical areas.la2 Fleet and associates3 noted that the brain structures related to this syndrome are heavily dopamine innervated. In clinical recovery of neglect in animals, dopamine pathway activity increases.4 Dopamine agonists, including amphetamine,5 bromocriptine and apomorphine,3s6-9 and metbylphenidate,9 may improve neglect after brain injury in animals and humans. We studied a patient with akinesia, abulia, and left-sided neglect after a right hemisphere stroke. We wished to confirm our clinical suspicion that his neglect reflected motor-From the

View PDFchevron_right
Regulation of firing of dopaminergic neurons and control of goal-directed behaviors
Anthony Grace

Trends in Neurosciences, 2007

There are several brain regions that have been implicated in the control of motivated behavior and whose disruption leads to the pathophysiology observed in major psychiatric disorders. These systems include the ventral hippocampus, which is involved in context and focus on tasks, the amygdala, which mediates emotional behavior, and the prefrontal cortex, which modulates activity throughout the limbic system to enable behavioral flexibility. Each of these systems has overlapping projections to the nucleus accumbens, where these inputs are integrated under the modulatory influence of dopamine. Here, we provide a systems-oriented approach to interpreting the function of the dopamine system, its modulation of limbic-cortical interactions and how disruptions within this system might underlie the pathophysiology of schizophrenia and drug abuse.

View PDFchevron_right
Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Merce Correa

Current Psychiatry Reviews, 2006

The notion that motivated behaviors having an energetic or activational component is an old one, and there are numerous examples of this idea from the literatures of psychology and ethology. Behavioral researchers have demonstrated that vigor or persistence of work output in stimulus-seeking behavior is a fundamental aspect of motivation. In addition, psychiatrists and clinical psychologists have come to emphasize the importance of energy-related dysfunctions, such as psychomotor slowing and apathy, in various clinical syndromes. Because of the potential scientific importance and clinical relevance of behavioral activation processes, it is critical to determine the brain mechanisms that are involved. Considerable evidence indicates that DA in nucleus accumbens is involved in activational aspects of motivation. Accumbens DA depletions decrease spontaneous, stimulant-induced, and food-induced motor activity. In addition, the effects of accumbens DA depletions on food-seeking behavior depend greatly upon the response requirements of the task. Research involving concurrent choice tasks has shown that rats with accumbens DA depletions reallocate their instrumental behavior away from food-reinforced tasks that have high response requirements, and instead select a less-effortful type of food-seeking behavior. Rats with accumbens DA depletions are particularly sensitive to lever pressing schedules with high ratio requirements (i.e., a large number of lever presses must be emitted for reinforcement to occur). Together with studies of frontal cortex function in animals, and clinical studies on neurochemical and other functional changes in the human brain, this line of research could have implications for understanding the brain circuitry involved in energy-related psychiatric disorders such as psychomotor slowing in depression, anergia, fatigue and apathy.

View PDFchevron_right
Contrasting effects of dopamine and glutamate receptor antagonist injection in the nucleus accumbens suggest a neural mechanism underlying cue-evoked goal-directed behavior
Howard Fields

European Journal of Neuroscience, 2004

Discriminative stimuli (DSs) inform animals that reward can be obtained contingent on the performance of a specific behavior. Such stimuli reinstate drug-seeking behavior, evoke dopamine release in the nucleus accumbens (NAc) and excite and inhibit specific subpopulations of NAc neurons. Here we show in rats 2 that DSs can reinstate food-seeking behavior. In addition, we compare the effects of injecting dopamine receptor antagonists into the NAc with those of general NAc inactivation on the performance of a DS task. Selective antagonism of D1 receptors reduced responding to the DS and increased the latency to respond, whereas general inactivation of NAc neuronal activity increased the latency to respond to the DS and increased behaviors extraneous to the task, such as responding in the absence of cues and responding on the inactive lever. Based on these results and our previous findings that NAc neuronal responses to DSs are dependent on the ventral tegmental area, we propose a model for the functional role of NAc neurons in controlling behavioral responses to reward-predictive stimuli.

View PDFchevron_right
Complex motor and sensorimotor functions of striatal and accumbens dopamine: involvement in instrumental behavior processes
John Salamone

Psychopharmacology, 1992

The suggestions that dopamine (DA) systems are involved in "motor control" and "reward" represent the classic working hypotheses on the behavioral functions of these systems. The research generated by these hypotheses has yielded results that are far more complicated than the simplest form of either hypothesis would indicate. Pharmacological or lesion-induced interference with DA function does not suppress all aspects of movement control, nor all aspects of reward, nor all aspects of motivation. The deficits produced by interference with DA systems are selective and dissociative in nature, affecting some aspects of motor or motivational function, but leaving others basically intact. In some sense the hypotheses that DA is involved in "motor" or "reward" or "motivational" processes are partly correct, but the processes to which these terms refer are too broad to offer an accurate and detailed description of the behavioral functions of brain DA. A review of the literature on the behavioral pharmacology of DA suggests that the behaviors most easily disrupted by DA antagonists are highly activated and complex learned instrumental responses that are elicited or supported by mild conditioned stimuli, and maintained for considerable periods of time. It is proposed that DA in accumbens and striatum modulates the ability of neocortical and limbic areas involved in sensory, associative, and affective processes to influence complex aspects of motor function, and also modulates the execution of complex motor acts organized by the neocortex. Thus, interference with DA systems produces a "subcortical apraxia", which dissociates complex stimulus processes from complex motor processes, but leaves aspects of those processes intact.

View PDFchevron_right
Dopaminergic Mechanisms in Actions and Habits
Jeffery Wickens

Journal of Neuroscience, 2007

Recent studies suggest new ways to interpret dopaminergic actions in goal-directed performance and habitual responding. In the early stages of learning dopamine plays an essential role, but with extended training dopamine appears to play a decreasing role in response expression. Experimental manipulation of dopamine levels alters the correlation of cortical and striatal neural activity in behaving animals, and these dopamine-dependent changes in corticostriatal correlations may be reflected in changes in action selection in the basal ganglia. Consistent with this hypothesis, changes in dopamine signaling brought about by sensitization with amphetamine mimic the transition from goal-directed to habit-based instrumental performance. At the cellular level, dopamine-dependent synaptic plasticity may be important initially, and subsequently lead to more persistent changes that no longer require dopamine. The locus of these actions within the cortical and corticostriatal circuitry is a focus on ongoing research.

View PDFchevron_right
Differential Expression of Motivational Stimulus Properties by Dopamine in Nucleus Accumbens Shell versus Core and Prefrontal Cortex
Maria Antonietta De Luca

The Journal of Neuroscience, 2002

View PDFchevron_right
Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine
S. Mingote, Merce Correa, John Salamone

Current Opinion in Pharmacology, 2005

According to the dopamine (DA) hypothesis of reward, DA systems in the brain, particularly in the nucleus accumbens, are thought to directly mediate the rewarding or primary motivational characteristics of natural stimuli such as food, water and sex, as well as various drugs of abuse. However, there are numerous problems associated with this hypothesis. Interference with accumbens DA transmission does not substantially blunt primary motivation for natural rewards such as food, but it does disrupt the propensity of animals to engage in effortful responding to obtain food. Electrophysiological and voltammetric studies indicate that novel stimuli, conditioned stimuli that predict reward, and instrumental behaviors that deliver natural rewards all act to stimulate DA activity. Accumbens DA acts as a modulator of several functions related to motivated behavior, and can influence normal and pathological cognitive function, activational aspects of motivation, anergia or psychomotor slowing in depression, the impact of conditioned stimuli, plasticity and a variety of sensorimotor functions.

View PDFchevron_right

References (116)

  1. Jastrow J. Will (disorders of). In: Baldwin J. M. ed. Dictionary of Philosophy and Psychology, vol. 2. London: MacMillan, 1901.
  2. Fisher C. M. Honoured guest presentation: abulia minor vs. agitated behavior. Clin Neurosurg 1983; 31: 9-31.
  3. Berrios G. E., Gili M. Abulia and impulsiveness revisited: a conceptual history. Acta Psychiatr Scand 1995; 92: 161-167.
  4. Drubach D. A., Zeilig G., Perez J., Peralta L., Makley M. Treatment of abulia with Carbidopa/Levadopa. Journal of Neurologic Rehabilitation 1995; 9: 151-155.
  5. Caplan L. R., Schmahmann J. D., Kase C. S. et al. Caudate infarcts. Arch Neurol 1990; 47: 133-143.
  6. Marin R. S. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3: 243-254.
  7. Laplane D. Loss of psychic self-activation. Rev Neurol (Paris) 1990; 146: 397-404.
  8. Naville F. Les complications des sequelles mentales de l'encephalite epidemique. L'encephale 1922; 17: 369-375.
  9. Hassler R. Extrapyramidal-motorische systeme und Erkrankungen. In: Handbuck der Innerin Medezin, vol. 3. Berlin: Springer 1953: 676-904.
  10. Arieti S. Schizophrenia: the manifest symptomatology, the psychodynamic and formal mechanisms. In: Arieti S. eds. American Handbook of Psychiatry, vol. 1, New York: Basic Books Inc 1959: 455-484.
  11. Ribot T. La Psychologie des Sentiments. Felix Alcan: Paris, 1886.
  12. Cutting J. The role of right hemisphere disfunction in psychiatric disorders. Br J Psychiatry 1992; 180: 583-588.
  13. Bermanzohn P. C., Siris S. G. Akinesia -a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry 1992; 33: 221-232.
  14. Cairns H., Oldfied R. C., Pennybacker J. B., Whitteridge D. Akinetic mutism with an epidermoid cyst of the 3rd ventricle. Brain 1941; 64: 273-290.
  15. Trillet M., Croisile B., Tourniaire D., Schott D. Disorders of voluntary motor activity and lesions of caudate nuclei. Rev Neurol Paris 1990; 146: 338-344.
  16. Blum K., Cull J. G., Braverman E. R., Comings D. E. Reward deficiency syndrome. Am Sci 1996; 84: 132-145.
  17. Willner P. Animal-models of depression -validity and applications. Adv Biochem Psychopharmacol 1995; 49: 19-41.
  18. Trovero F., Blanc G., Herve D., Vezina P., Glowinski J., Tassin J. P. Contribution of an alpha-1-adrenergic receptor subtype to the expression of the ventral tegmental area syndrome. Neuroscience 1992; 47: 69-76.
  19. Van Reekum R., Bayley M., Garner S., Burke I. M., Fawcett S., Hart A., Thompson W. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995; 9: 49-53.
  20. Alexander G. E., DeLong M. R., Strick P. L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381.
  21. Middleton F. A., Strick P. L. Basal ganglia and cerebellar output influences non-motor function. Mol Psychiatry 1996; 1: 429-433.
  22. Baddeley A., Wilson B. Frontal amnesia and the Dysexecutive Syndrome. Brain Cogn 1988; 7: 212-230.
  23. Starkstein S. E., Fedoroff J. P., Price T. R., Leiguarda R., Robinson, R.G. Apathy following cerebrovascular lesions. Stroke 1993; 24: 1625-1630.
  24. Galynker I. I., Levinson I., Miner C., Rosenthal R. Negative symptoms in patients with basal ganglia strokes. Neuropsychiatry Neuropsychol Behav Neurol 1995; 8: 113-117.
  25. Kaelin D. L., Cifu D. X., Matthies B. Methylphenidate effect on attention deficit in the acutely brain-injured adult. Arch Phys Med Rehabil 1996; 77: 6-9.
  26. Brown P., Marsden C. D. What do the basal ganglia do? Lancet 1998; 351: 1801-1804.
  27. Masterman D. L., Cummings J. L. Frontal-subcortical circuits: the anatomical basis of executive, social and motivated behaviours. J Psychopharmacol 1997; 11: 107-114.
  28. Robbins T. W., Everitt B. Neurobehavioural mechanism of reward and motivation. Curr Opin Neurobiol 1996; 6: 228-236.
  29. Watanabe M. Reward expectancy in primate prefrontal neurons. Nature 1996; 382: 629-632.
  30. Saint-Cyr J. A., Taylor A. E., Trepanier L., Lang A. E. The caudate nucleus: head ganglion of the habit system. In: Vallar G., Wallesch C. eds. Neuropsychological Impairments Associated with subcortical lesions. Oxford: Oxford University Press 1992; 204-226.
  31. Fibiger H. C., Phillips A. G. Role of catecholamine transmitters in brain reward systems: implications for the neurobiology of affect. In: Angel J., Oreland L. eds. Brain Reward Systems and Abuse: Seventh International Berzelius, 1987. Symposium. New York: Raven Press 1987: 61-74.
  32. Al-Adawi S., Powell J. H., Greenwood R. J. Motivational deficits after brain injury: a neuropsychological approach using new assessment techniques. Neuropsychology 1998; 12: 115-124.
  33. Powell J. H., Al-Adawi S., Morgan J., Greenwood, R. J. Motivation deficits after brain injury: effects of bromocriptine in 11 patients. J Neurol Neurosurg Psychiatry 1996; 60: 416-421.
  34. Narabayashi H. Pallidotomy revisited. Analysis of posteroventral pallidotomy. Stereotact Funct Neurosurg 1997; 69: 54-61.
  35. Mogenson G. J., Jones D. L., Yim C. Y. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 1980; 14: 69-97.
  36. Mrabet A., Hammouda I. M. B., Abroug Z., Smiri W., Haddad A. Akinetic mutism and abulia -Clinical expression of a reticulo-cortical integration defect. Rev Neurol (Paris) 1995; 151: 359.
  37. Marshall J. F., Teitelbaum P. Further analysis of sensory inattention following lateral hypothalamus damage in rats. J Physiol Psychol 1974; 86: 375-395.
  38. Bindra D. A motivational view of learning, performance and behavior modification. Psychol Rev 1974; 81: 199-213.
  39. Lader M. Neuroleptic-induced deficit syndrome: old problem, new challenge. J Pharmacol 1993; 7: 392-393.
  40. Gallistel C. R., Karras D. Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol Biochem Behav 1984; 20: 73-77.
  41. Koob G. F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52-58.
  42. Mortimer W. G. History of Coca. San Francisco: Fitz Hugh Ludlow Memorial Library, 1974.
  43. Kiyatkin E. A. Dopamine mechanism of cocaine addiction. Int J Neurosci 1994; 78: 75-101.
  44. Fowler J. S., Volkow N. D., Wang G. J. et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379: 733-736.
  45. Al-Adawi S., Powell J. The influence of smoking on reward responsiveness and cognitive functions: a natural experiment. Addiction 1997; 92: 1773-1782.
  46. Brower K. J., Maddahian E., Blow F. C., Beresford T. P. A comparison of self-reported symptoms and DSM-III-R criteria for cocaine withdrawal. Am J Drug Alcohol Abuse 1988; 14: 347-356.
  47. Harris G., Aston-Jones G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 1994; 371: 155-157.
  48. Weiss F., Markou A., Lorang M. T., Koob G. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access. Brain Res 1992; 593: 314-318.
  49. Dackis C. A., Gold M. S. Bromocriptine as treatment of cocaine abuse. Lancet 1985; 1: 1151-1152.
  50. Al-Adawi S., Powell J., Greenwood R. Motivation deficit following brain injury. J Psychopharmacol 1994; 8: AS28.
  51. Bhatia K. P., Marsden C. D. The behavioral and motor consequences of focal lesions of the basal ganglia in man. Brain 1994; 117: 859-876.
  52. Cummings J. L. Clinical Neuropsychiatry. New York: Grune and Stratton, 1985.
  53. Blumer D., Benson D. F. Personality changes with frontal and temporal lobe lesion. In: Blumer D., Benson D. F. eds. Psychiatric Aspects of Neurologic Disease. New York: Grune and Stratton 1975: 151-169.
  54. Eslinger P. J., Gratton L. M. Frontal lobe and frontal-striatal substrate for different forms of human cognitive flexibility. Neuropsychologia 1993; 31: 17-28.
  55. Ackermann H., Ziegler W. Akinetic mutism-a review of the literature. Fortschr Neurol Psychiatr 1995; 63: 59-67.
  56. Bareggi S. R., Porta M., Selenati A. et al. Homovanillic acid and 5-hydroxyindol acetic acid in the CSF patients after severe head injury. Eur Neurol 1975; 13: 545-554.
  57. Vecht C. J., Van Woerkom T. C. A. M., Teelken A. W., Minderhoud J. M. Homovanillic acid and 5-hydroxyindo- leascetic acid cerebro-spinal fluid levels. Arch Neurol 1975; 32: 792-797.
  58. Yang S. Y., Zhang S., Wang M. L. Clinical significance of admission hyperglycaemia and factors related to it in patients with acute severe head injury. Surg Neurol 1995; 44: 373-377.
  59. Eames P. The use of Sinement and bromocriptine. Brain Inj 1989; 3: 319-320.
  60. Barrett K. Treating organic abulia with bromocriptine and lisuride: four case studies. J Neurol Neurosurg Psychiatry 1991; 54: 718-721.
  61. Kraepelin E. Die Erscheinungsformen des Irresciens. In: Themes and Variation in European Psychiatry S.R. Hirsch and M. Shepherd (1974). Bristol: John Wright, 1920.
  62. Ellenbroek B. A., Willemen A. P., Cools A. R. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 1989; 2: 191-199.
  63. Dixon A. K., Huber C., Lowe D. A. Clozapine promotes approach-oriented behavior in male mice. J Clin Psychiatry 1994; 55: 4-7.
  64. Andreasen N.C. (1989). Neural mechanism of negative symptoms. Br J Psychiatry Suppl. 1989; 7: 93-98.
  65. Takigawa M., Maeda H., Ueyama K., Tominaga H., Matsumoto K. A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia. Can J Physiol Pharmacol 1993; 71: 321-325.
  66. Bornstein R. A., Schwarzkopf S. B., Olson S. C., Nasrallah H. A. Third-ventricle enlargement and neuropsychological deficit in schizophrenia. Biol Psychiatry 1992; 31: 954-961.
  67. Crow T. J. Brain changes and negative symptoms in schizophrenia. Psychopathology 1995; 28: 18-21.
  68. Chouinard G., Jones, B. D. Schizophrenia as a dopamine deficiency disease. Lancet 1978; 2: 99-100.
  69. Martinot J. L., Paillere-Martinot M. I., Loc'h C. et al. Central D2 receptors and negative symptoms of schizophrenia. Br J Psychiatry 1994; 164: 27-32.
  70. Okubo Y., Suhara T., Suzuki K. et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-636.
  71. Ribeyre J. M., Lesieur P., Varoquaux O., Dollfus S., Pays M., Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 1994; 36: 230-236.
  72. Ohmori T., Koyama T., Inoue T., Matsubara S., Yamashita I. B- HT 920, a dopamine D2 Agonist, in the treatment of Negative Symptom of chronic schizophrenia. Biol Psychiatry 1993; 33: 687-693.
  73. Kane J. M., Mayerhoff D. Do negative symptoms respond to pharmacological treatment? Symposium: Negative symptoms in schizophrenia. Br J Psychiatry 1989; 155: 115-118.
  74. Levi-Minzi S., Bermanzohn P. C., Siri S. G. Bromocriptine for "negative" schizophrenia. Compr Psychiatry 1991; 32: 210-216.
  75. King K. J. Dopamine agonists for negative symptoms in schizophrenia. Br J Clin Pharmacol 1978: 6: 541-542.
  76. Paillere-Martinot M. L., Lecrubier Y., Martinot J. L., Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995; 152: 130-134.
  77. Lindenmayer J. P. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr Scand 1995; 388 (suppl.): 15-19.
  78. Frith C. D. The cognitive neuropsychology of schizophrenia. Hove: Lawrence Erlbaum Associate Ltd, 1992.
  79. Hemsley D. R. Cognitive impairment in schizophrenia. In: Burton A., ed. The Pathology and Psychology of Cognition. London: Methuen 1982: 169-203.
  80. Rosenbaum G., MacKavey W. R., Grisell J. L. Effects of biological and social motivation in schizophrenia reaction time. J Abnorm Soc Psychol 1957; 53: 364-368.
  81. Liddle P. F., Morris D. L. Schizophrenia Syndromes and Frontal Lobe performance. Br J Psychiatry 1991; 158: 340-345.
  82. Miller E. Verbal fluency as a function of measure of verbal intelligence and in relation to different types of cerebral pathology. Br J Clin Psychol 1984; 23: 53-57.
  83. Wilkin A., Sanfilipo M., Wolf A. P., Angrist B., Brodie J. D., Rostrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Br J Clin Psychol 1992; 49: 959-965.
  84. Volkow N. D., Wolf A. P., Van Gelder P. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry 1987; 144: 151-158.
  85. Weinberger D. R., Berman K. F., Zec R. F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: 1 Regional cerebral blood flow (RCBF) evidence. Arch Gen Psychiatry 1986; 43: 114-125.
  86. Liddle P. F., Friston K. J., Frith C. D., Frockowiak R. S. Cerebral blood flow and mental processes in schizophrenia. J R Soc Med 1992; 85: 224-227.
  87. Bilder R. M., Lieberman J. A., Kim Y., Alvier J. M., Reiter G. Methylphenidate and neurological effects on oral word production in schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 1992; 5: 262-271.
  88. Daniel D. G., Weinberger D. R., Jones D. W. et al. The effects of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 1991; 11: 1907-1917.
  89. Marsden C. D. The mysterious motor function of the basal ganglia: the Robert Wartenberg lecture. Neurology 1980; 32: 514-539.
  90. Menza M. A., Golbe L. I., Cody R. A., Forman N. E. Dopamine- related personality traits in Parkinson's disease. Neurology 1993; 43(3 part 1), 505-508.
  91. Starkstein S. E., Mayberg H. S., Preziosi T. J., Andrezejewski P., Leiguarda R., Robinson R. G. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134-139.
  92. Yahr M. Parkinsonism. In: Rowland L. P. ed. Merritt's Textbook of Neurology, 8th edn., Kent: Lea and Febinger 1989: 658-671.
  93. Plummer A., Earl A., Scheider J., Trapold J., Barrett W. Pharmacology of Rauwolfia alkaloids, including reserpine. Ann N Y Acad Sci 1954; 59: 8-21.
  94. Davis G., Williams A. C., Markey S., Ebert M., Caine E., Reichert C., Kopin I. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1: 249-254.
  95. Langston J. W., Ballard P., Tetrud J., Irwin I. Chronic parkinsonism in humans due to a product of meperidine- analog synthesis. Science 1983; 219: 979-980.
  96. German D. C., Dubach M., Askari S., Speciale S. G., Bowden D. M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 1988; 24: 161-174.
  97. Baik J. H., Picetti R., Saiardi A. et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995; 377: 424-428.
  98. Miyashita N., Hikosaka O., Kato M. T. I. Visual hemineglect induced by unilateral striatal dopamine deficiency in monkeys. Neuroreport 1995; 6: 1257-1260.
  99. Ehringer H., Hornykiewicz O. Vertielung von Noradrenalin und Dopamine (3-hydroxytyramine) in Gehirn des Menschen und der Verhalten bei Erkrankunger des extrapyramiden Systems. Klin Wochenschr 1960; 38: 1236-1239.
  100. Marsden C. D. Dopamine and basal ganglia disorders in humans. Sem Neurosci 1992; 4: 171-179.
  101. Koller W. C. When does Parkinson's disease begin? Neurology 1992; 42(Suppl 4): 27-31.
  102. Brooks D. J. Detection of preclinical Parkinson's disease with PET. Neurology 1991; 41: 24-27.
  103. Van Praag H. M., Korf J., Lakke J. P. W. F., Schut T. Dopamine metabolism in depression, psychoses and Parkinson's Disease: The problem of the specificity of biological variables in behavior disorders. Psychol Med 1975; 5: 138-146.
  104. Sacks O. Awakening. New York: Dutton, 1973.
  105. Lindvall O., Sawle G., Widner H. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-180.
  106. Sawle G. V., Lindvall O., Bjorklund A., Frackowiak R. S. J., Brooks D.J. Long terms effects of foetal mesencephalic transplantation; PET evidence of graft survival 3 years from operation. Neurology 1993; 43 (suppl.2): A179.
  107. Morris R. G., Downes J. J., Evenden J. L., Sahakian B. J., Heald A., Robbin T. W. Planning and spatial working memory in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 757-766.
  108. Cummings J. L. Depression and Parkinson's disease. Am J Psychiatry 1992; 149: 443-454.
  109. Weddell R. A., Weiser R. A double-blind cross-over placebo- controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinson's disease. Behav Pharmacol 1995; 6: 81-91.
  110. Brown R. G., Marsdsen C. D. Cognitive function in Parkinson's disease: from description to theory. TINS 1990; 13: 21-29.
  111. Philips S. G., Carr G. D. Cognition and the basal ganglia: a possible substrate of procedural knowledge. Can J Neurol Sci 1987; 14: 381-385.
  112. Playford E. D., Jenkins I. H., Passingham R. E., Nutt J., Frockowiak R.S., Brooks D.J. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992; 32: 151-161.
  113. Lange K. W., Robbins T. W., Marsden C. D., James M., Owen A. M., Paul G. M. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992; 107: 394-404.
  114. Le Moal M. Mesocorticolimbic dopaminergic neurons. In: Bloom F. E., Kupfer D. J., eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 283-294.
  115. Koob G. F. The dopamine anhedonia hypothesis: a pharmacological phrenology. BehaviBrain Sci 1982; 5: 63-64.
  116. Blackburn J. R., Pfaus J. G., Phillips A. G. Dopamine functions in appetitive and defensive behavior. Prog Neurobiol 1992; 39: 247-279.

Related papers

The involvement of nucleus accumbens dopamine in appetitive and aversive motivation
John Salamone

Behavioural Brain Research, 1994

In recent years, considerable emphasis has been placed upon the putative role of nucleus accumbens dopamine systems in appetitive motivation and positive reinforcement. However, considerable evidence indicates that brain dopamine in general, and nucleus accumbens dopamine in particular, is involved in aspects of aversive motivation. Administration of dopamine antagonists or localized interference with nucleus accumbens dopamine systems has been shown to disrupt active avoidance behavior. In addition, accumbens dopamine release and metabolism is activated by a wide variety of stressful conditions. A review of the literature indicates that there are substantial similarities between the characteristics of dopaminergic involvement in appetitive and aversive motivation. There is conflicting evidence about the role of dopamine in emotion, and little evidence to suggest that the profound and consistent changes in instrumental behavior produced by interference with DA systems are due to direct dopaminergic mediation of positive affective responses such as hedonia. It is suggested that nucleus accumbens dopamine is involved in aspects of sensorimotor functions that are involved in both appetitive and aversive motivation.

View PDFchevron_right
Reduced dopamine function within the medial shell of the nucleus accumbens enhances latent inhibition
helen cassaday

Pharmacology Biochemistry and Behavior, 2011

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues. Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited. In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit: http://www.elsevier.com/copyright

View PDFchevron_right
Accumbens dopamine-acetylcholine balance in approach and avoidance
Pedro Rada

Current Opinion in Pharmacology, 2007

Understanding systems for approach and avoidance is basic for behavioral neuroscience. Research on the neural organization and functions of the dorsal striatum in movement disorders, such as Huntington's and Parkinson's Disease, can inform the study of the nucleus accumbens (NAc) in motivational disorders, such as addiction and depression. We propose opposing roles for dopamine (DA) and acetylcholine (ACh) in the NAc in the control of GABA output systems for approach and avoidance. Contrary to DA, which fosters approach, ACh release is a correlate or cause of meal satiation, conditioned taste aversion and aversive brain stimulation. ACh may also counteract excessive DA-mediated approach behavior as revealed during withdrawal from drugs of abuse or sugar, when the animal enters an ACh-mediated state of anxiety and behavioral depression. This review summarizes evidence that ACh is important in the inhibition of behavior when extracellular DA is high and the generation of an anxious or depressed state when DA is relatively low. Recent reviews emphasize a fascinating feature of the basal ganglia, movement system. It is now believed to be comprised of not just the one classic "loop" from the dorsal striatum to the substantia nigra and back, but rather a linked set of loops, or a "spiral" . Three main loops have recently been characterized. Starting along the midline, one loop carries information

View PDFchevron_right
The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking
Jaak Panksepp

Brain Research Reviews, 1999

Ž . Studies addressing behavioral functions of dopamine DA in the nucleus accumbens septi NAS are reviewed. A role of NAS DA in ) Corresponding author. 0165-0173r99r$ -see front matter q 1999 Elsevier Science B.V. All rights reserved.

View PDFchevron_right
Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior
Anthony Grace

2005

Goal-directed behavior is believed to involve interactions of prefrontal cortical and limbic inputs in the nucleus accumbens (NAcc), and their modulation by mesolimbic dopamine (DA) seems to be of primary importance in NAcc function. Using in vivo electrophysiological recordings simultaneously with DA system manipulation in rats, we show that tonic and phasic DA release selectively modulates hippocampal and prefrontal cortical inputs through D1 and D2 receptors, respectively. In addition, we also found that D1 activation and D2 inactivation in the NAcc produced behaviorally selective effects (learning versus set shifting of response strategy) that correspond to specific afferents. These results suggest that the dynamics of DA release regulate the balance between limbic and cortical drive through activation and inactivation of DA receptor subtypes in the accumbens, and this regulates goal-directed behavior.

View PDFchevron_right

Related topics

  • Rehabilitation
  • Dopaminergic Neurotransmision
  • Goal-Directed Behavior
  • Goal-Directed Action
    • 580 California St., Suite 400
    San Francisco, CA, 94104
    © 2025 Academia. All rights reserved